QURENasdaqPharmaceutical PreparationsFiscal year ends December 31
uniQure N.V.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 29, 2026
$22.20+0.42 (+1.93%)
Close on Oct 19, 2026
- Market cap
- $1.47B
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Who owns uniQure's shares
Held by institutions
–
Shares held, 13F filers
Institutional holders
–
Net institutional buying
–
Insider trades, 12 months
0 buys · 57 sales
Net sold $22.08M
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Avoro Capital Advisors LLC | 6,150,000 | 9.87% | 13G (passive) amendment | Dec 31, 2025 |
| FMR LLC | 6,059,574 | 9.80% | 13G (passive) | Sep 30, 2025 |
| JPMorgan Chase & Co. | 5,951,794 | 8.50% | 13G (passive) amendment | Sep 30, 2026 |
| JPMorgan Chase & Co | 4,866,211 | 7.00% | 13G (passive) | Jun 30, 2026 |
| Vestal Point Capital, LP | 4,792,572 | 8.90% | 13G (passive) amendment | Mar 31, 2025 |
| Roderick Wong, M.D. | 4,265,428 | 7.90% | 13G (passive) | Mar 31, 2025 |
| RTW Investments, LP | 3,941,572 | 5.70% | 13G (passive) | Jun 30, 2026 |
| Roderick Wong | 3,711,462 | 6.00% | 13G (passive) amendment | Dec 31, 2025 |
| Aberdeen Group plc | 3,678,640 | 5.91% | 13G (passive) amendment | Dec 31, 2025 |
| Behzad Aghazadeh | 3,625,000 | 6.60% | 13G (passive) | Jun 30, 2025 |
| SIG Brokerage, LP | 3,536,485 | 5.70% | 13G (passive) | Dec 31, 2025 |
| Nantahala Capital Management, LLC | 2,982,013 | 6.12% | 13G (passive) amendment | Sep 30, 2024 |
| Joe Lewis | 2,500,000 | 5.10% | 13G (passive) | Jul 10, 2024 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Matthew C. Kapusta | CEO, Managing Director | 531,109 | 0.77% | Jul 7, 2026 |
| Walid Abi-Saab | Chief Medical Officer | 168,235 | 0.24% | Jul 2, 2026 |
| Jeannette Potts | Chief Legal Officer | 133,246 | 0.19% | Jun 17, 2026 |
| Kylie O'Keefe | Chief Customer & Strat Officer | 108,864 | 0.16% | Jun 12, 2026 |
| Christian Klemt | Chief Financial Officer | 238,581 | 0.34% | Mar 6, 2026 |
| Jack Kaye | Director | 43,056 | 0.06% | Jul 2, 2026 |
| Madhavan Balachandran | Director | 49,644 | 0.07% | Jun 22, 2026 |
| Robert Gut | Director | 32,259 | 0.05% | Jun 12, 2026 |
| Jeremy P. Springhorn | Director | 43,251 | 0.06% | Jun 12, 2026 |
| Rachelle Suzanne Jacques | Director | 33,903 | 0.05% | Jun 12, 2026 |
| David D. Meek | Director | 39,747 | 0.06% | Jun 12, 2026 |
| Leonard E. Post | Director | 35,494 | 0.05% | Jun 12, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Matthew C. Kapusta CEO, Managing Director | Jul 2, 2026 | Sale(10b5-1 plan) | −9,200 | $44.43 | $408.76K | 531,109 |
| Matthew C. Kapusta CEO, Managing Director | Jul 2, 2026 | Sale(10b5-1 plan) | −4,282 | $45.43 | $194.53K | 526,827 |
| Matthew C. Kapusta CEO, Managing Director | Jul 2, 2026 | Sale(10b5-1 plan) | −7,600 | $45.89 | $348.76K | 519,227 |
| Matthew C. Kapusta CEO, Managing Director | Jul 2, 2026 | Option exercise | +21,082 | $19.39 | $408.78K | 540,309 |
| Walid Abi-Saab Chief Medical Officer | Jun 30, 2026 | Sale(10b5-1 plan) | −10,000 | $46.46 | $464.60K | 168,235 |
| Walid Abi-Saab Chief Medical Officer | Jun 30, 2026 | Sale(10b5-1 plan) | −20,000 | $46.40 | $928.00K | 148,235 |
| Walid Abi-Saab Chief Medical Officer | Jun 30, 2026 | Option exercise | +10,000 | $5.59 | $55.90K | 178,235 |
| Jack Kaye Director | Jun 30, 2026 | Option exercise | +17,060 | $20.18 | $344.27K | 43,056 |
| Jack Kaye Director | Jun 30, 2026 | Sale(10b5-1 plan) | −4,107 | $46.49 | $190.93K | 25,996 |
| Jack Kaye Director | Jun 30, 2026 | Option exercise | +4,107 | $37.00 | $151.96K | 30,103 |
| Jack Kaye Director | Jun 30, 2026 | Sale(10b5-1 plan) | −17,060 | $46.43 | $792.10K | 25,996 |
| Walid Abi-Saab Chief Medical Officer | Jun 26, 2026 | Sale | −1,434 | $46.86 | $67.20K | 168,235 |
| Matthew C. Kapusta CEO, Managing Director | Jun 25, 2026 | Sale(10b5-1 plan) | −28,716 | $50.02 | $1.44M | 519,227 |
| Matthew C. Kapusta CEO, Managing Director | Jun 25, 2026 | Option exercise | +28,716 | $31.71 | $910.58K | 547,943 |
| Matthew C. Kapusta CEO, Managing Director | Jun 24, 2026 | Option exercise | +4,128 | $31.71 | $130.90K | 525,923 |
| Matthew C. Kapusta CEO, Managing Director | Jun 24, 2026 | Sale(10b5-1 plan) | −6,696 | $50.00 | $334.80K | 519,227 |
| Matthew C. Kapusta CEO, Managing Director | Jun 18, 2026 | Option exercise | +4,656 | $31.71 | $147.64K | 563,466 |
| Matthew C. Kapusta CEO, Managing Director | Jun 18, 2026 | Sale(10b5-1 plan) | −4,656 | $50.00 | $232.80K | 558,810 |
| Matthew C. Kapusta CEO, Managing Director | Jun 18, 2026 | Sale(10b5-1 plan) | −37,015 | $50.00 | $1.85M | 521,795 |
| Jack Kaye Director | Jun 17, 2026 | Sale(10b5-1 plan) | −5,295 | $42.57 | $225.41K | 25,996 |
| Jack Kaye Director | Jun 17, 2026 | Option exercise | +5,295 | $31.71 | $167.90K | 31,291 |
| Matthew C. Kapusta CEO, Managing Director | Jun 17, 2026 | Sale(10b5-1 plan) | −56,929 | $43.43 | $2.47M | 603,729 |
| Matthew C. Kapusta CEO, Managing Director | Jun 17, 2026 | Sale(10b5-1 plan) | −6,023 | $43.70 | $263.21K | 693,239 |
| Matthew C. Kapusta CEO, Managing Director | Jun 17, 2026 | Sale(10b5-1 plan) | −23,977 | $42.61 | $1.02M | 699,262 |
| Matthew C. Kapusta CEO, Managing Director | Jun 17, 2026 | Option exercise | +62,581 | $19.39 | $1.21M | 723,239 |
| Matthew C. Kapusta CEO, Managing Director | Jun 17, 2026 | Sale(10b5-1 plan) | −33,334 | $45.01 | $1.50M | 570,395 |
| Matthew C. Kapusta CEO, Managing Director | Jun 17, 2026 | Sale(10b5-1 plan) | −11,585 | $48.65 | $563.61K | 558,810 |
| Matthew C. Kapusta CEO, Managing Director | Jun 17, 2026 | Sale(10b5-1 plan) | −32,581 | $45.02 | $1.47M | 660,658 |
| Madhavan Balachandran Director | Jun 17, 2026 | Sale(10b5-1 plan) | −5,295 | $47.08 | $249.29K | 49,644 |
| Madhavan Balachandran Director | Jun 17, 2026 | Sale(10b5-1 plan) | −4,700 | $43.66 | $205.20K | 44,944 |
| Madhavan Balachandran Director | Jun 17, 2026 | Sale(10b5-1 plan) | −1,690 | $42.60 | $71.99K | 43,254 |
| Madhavan Balachandran Director | Jun 17, 2026 | Option exercise | +6,390 | $19.39 | $123.90K | 54,939 |
| Madhavan Balachandran Director | Jun 17, 2026 | Option exercise | +5,295 | $31.71 | $167.90K | 48,549 |
| Madhavan Balachandran Director | Jun 15, 2026 | Option exercise | +10,000 | $8.49 | $84.90K | 53,254 |
| Madhavan Balachandran Director | Jun 15, 2026 | Sale(10b5-1 plan) | −10,000 | $27.85 | $278.50K | 43,254 |
| Jeannette Potts Chief Legal Officer | Jun 15, 2026 | Sale | −5,237 | $27.67 | $144.91K | 133,246 |
| Jeremy P. Springhorn Director | Jun 11, 2026 | Sale | −1,993 | $27.06 | $53.93K | 43,251 |
| Jack Kaye Director | Jun 11, 2026 | Sale | −1,993 | $27.06 | $53.93K | 25,996 |
| Madhavan Balachandran Director | Jun 11, 2026 | Sale | −1,993 | $27.06 | $53.93K | 43,254 |
| Kylie O'Keefe Chief Customer & Strat Officer | Jun 11, 2026 | Sale | −15,936 | $27.06 | $431.23K | 108,864 |
| Leonard E. Post Director | Jun 11, 2026 | Sale | −1,993 | $27.06 | $53.93K | 35,494 |
| Rachelle Suzanne Jacques Director | Jun 11, 2026 | Sale | −1,993 | $27.06 | $53.93K | 33,903 |
| David D. Meek Director | Jun 11, 2026 | Sale | −1,993 | $27.06 | $53.93K | 39,747 |
| Robert Gut Director | Jun 11, 2026 | Sale(10b5-1 plan) | −2,726 | $27.06 | $73.77K | 32,259 |
| Jeremy P. Springhorn Director | Jun 10, 2026 | Award | +7,550 | – | – | 45,244 |
| Jack Kaye Director | Jun 10, 2026 | Award | +7,550 | – | – | 27,989 |
| Madhavan Balachandran Director | Jun 10, 2026 | Award | +7,550 | – | – | 45,247 |
| Leonard E. Post Director | Jun 10, 2026 | Award | +7,550 | – | – | 37,487 |
| Rachelle Suzanne Jacques Director | Jun 10, 2026 | Award | +7,550 | – | – | 35,896 |
| David D. Meek Director | Jun 10, 2026 | Award | +7,550 | – | – | 41,740 |
| Robert Gut Director | Jun 10, 2026 | Award | +7,550 | – | – | 34,985 |
| Robert Gut Director | Jun 10, 2026 | Sale(10b5-1 plan) | −1,780 | $26.05 | $46.37K | 27,435 |
| Robert Gut Director | Jun 10, 2026 | Sale(10b5-1 plan) | −3,127 | $26.03 | $81.40K | 29,215 |
| Robert Gut Director | Jun 10, 2026 | Sale(10b5-1 plan) | −2,645 | $26.07 | $68.96K | 32,342 |
| Robert Gut Director | Jun 10, 2026 | Option exercise | +2,645 | $16.04 | $42.43K | 34,987 |
| Jack Kaye Director | Jun 3, 2026 | Option exercise | +2,645 | $16.04 | $42.43K | 23,084 |
| Jack Kaye Director | Jun 3, 2026 | Sale(10b5-1 plan) | −2,645 | $30.01 | $79.38K | 20,439 |
| Walid Abi-Saab Chief Medical Officer | May 8, 2026 | Sale(10b5-1 plan) | −20,000 | $25.00 | $500.00K | 169,669 |
| Walid Abi-Saab Chief Medical Officer | May 8, 2026 | Sale(10b5-1 plan) | −25,000 | $25.10 | $627.50K | 189,669 |
| Walid Abi-Saab Chief Medical Officer | May 8, 2026 | Option exercise | +25,000 | $5.59 | $139.75K | 214,669 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Matthew C. Kapusta Officer, Director, CEO AND MANAGING DIRECTOR | Jul 2, 2026 | 21,082 | $951.93K | Jul 2, 2026 | Stock option exercise and sale |
| Jack Kaye Director | Jun 30, 2026 | 21,167 | $983.03K | Jun 30, 2026 | Stock option exercise pursuant to 10b51 plan |
| Walid Abi-Saab Chief Medical Officer | Jun 30, 2026 | 30,000 | $1.39M | Jun 30, 2026 | Stock option exercise pursuant to 10b51 plan |
| Walid Abi-Saab Chief Medical Officer | Jun 26, 2026 | 1,434 | $67.20K | Jun 26, 2026 | Restricted Stock Units Vesting |
| Matthew C. Kapusta Officer, Director, CEO AND MANAGING DIRECTOR | Jun 25, 2026 | 28,716 | $1.44M | Jun 25, 2026 | Stock option exercise and sale |
| Matthew C. Kapusta Officer, Director, CEO AND MANAGING DIRECTOR | Jun 24, 2026 | 6,696 | $334.80K | Jun 24, 2026 | Vested Stock from PSU and RSU |
| Matthew C. Kapusta Officer, Director, CEO AND MANAGING DIRECTOR | Jun 18, 2026 | 41,671 | $1.93M | Jun 18, 2026 | Vested Stock from PSU and RSU |
| Matthew C. Kapusta Officer, Director, CEO AND MANAGING DIRECTOR | Jun 17, 2026 | 164,429 | $7.07M | Jun 17, 2026 | Vested Stock from PSU and RSU pursuant to 10b51 plan |
| Jack Kaye Director | Jun 17, 2026 | 5,295 | $225.39K | Jun 17, 2026 | Stock option exercise pursuant to 10b51 plan |
| Madhavan Balachandran Director | Jun 17, 2026 | 11,685 | $526.46K | Jun 17, 2026 | Stock option exercise and sale Pursuant to 10b5-1 plan |
| Jeannette Potts Officer, CHIEF LEGAL OFFICER | Jun 15, 2026 | 5,237 | $144.89K | Jun 15, 2026 | RESTRICTED STOCK UNITS VESTING |
| Jack Kaye Director | Jun 11, 2026 | 1,993 | $53.94K | Jun 11, 2026 | Restricted stock units vesting |
| David D. Meek Director | Jun 11, 2026 | 1,993 | $53.94K | Jun 11, 2026 | Restricted stock unit vesting |
| Leonard E. Post Director | Jun 11, 2026 | 1,993 | $53.94K | Jun 11, 2026 | Restricted stock unit vesting |
| Rachelle Suzanne Jacques Director | Jun 11, 2026 | 1,993 | $53.94K | Jun 11, 2026 | Restricted stock unit vesting |